MilliporeSigma, a leader in genome editing, today announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing MilliporeSigma's patent application claims covering CRISPR gene-editing technol
OncoSec announced the Company has been granted exclusive worldwide rights to Gaeta Therapeutics' portfolio of patents and applications covering the combination use of IL-12 DNA and ...
The rise in colon cases among younger adults that's been seen in the United States is also occurring in wealthier nations worldwide, new research shows.